Structure Therapeutics' (GPCR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Structure Therapeutics (NASDAQ:GPCR - Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $80.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. William Blair assumed coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Stock Up 0.4 %

NASDAQ:GPCR traded up $0.09 during mid-day trading on Tuesday, reaching $23.74. 731,787 shares of the stock were exchanged, compared to its average volume of 913,703. The stock has a market capitalization of $1.36 billion, a P/E ratio of -32.08 and a beta of -1.35. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $62.74. The company has a 50 day simple moving average of $20.17 and a 200-day simple moving average of $27.78.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. As a group, research analysts predict that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock valued at $1,985,000 after purchasing an additional 312 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares in the last quarter. ANTIPODES PARTNERS Ltd lifted its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares during the period. LPL Financial LLC boosted its stake in shares of Structure Therapeutics by 6.0% in the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in Structure Therapeutics by 12.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after acquiring an additional 843 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.